-
Something wrong with this record ?
Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis
M. Garcia Quesada, ME. Peterson, JC. Bennett, K. Hayford, SL. Zeger, Y. Yang, MK. Hetrich, DR. Feikin, AL. Cohen, A. von Gottberg, M. van der Linden, NM. van Sorge, LH. de Oliveira, S. de Miguel, I. Yildirim, DF. Vestrheim, JR. Verani, E. Varon,...
Language English Country United States
Document type Journal Article
Grant support
001
World Health Organization - International
NLK
ProQuest Central
from 2001-08-01 to 2 months ago
Nursing & Allied Health Database (ProQuest)
from 2001-08-01 to 2 months ago
Health & Medicine (ProQuest)
from 2001-08-01 to 2 months ago
Public Health Database (ProQuest)
from 2001-08-01 to 2 months ago
- MeSH
- Global Health MeSH
- Child MeSH
- Adult MeSH
- Infant MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Immunization Programs MeSH
- Pneumococcal Infections * prevention & control epidemiology microbiology MeSH
- Pneumococcal Vaccines * administration & dosage MeSH
- Child, Preschool MeSH
- Aged MeSH
- Serogroup * MeSH
- Streptococcus pneumoniae * classification immunology MeSH
- Vaccines, Conjugate administration & dosage MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Infant MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Child, Preschool MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: Widespread use of pneumococcal conjugate vaccines (PCVs) has reduced vaccine-type invasive pneumococcal disease (IPD). We describe the serotype distribution of IPD after extensive use of ten-valent PCV (PCV10; Synflorix, GSK) and 13-valent PCV (PCV13; Prevenar 13, Pfizer) globally. METHODS: IPD data were obtained from surveillance sites participating in the WHO-commissioned Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project that exclusively used PCV10 or PCV13 (hereafter PCV10 and PCV13 sites, respectively) in their national immunisation programmes and had primary series uptake of at least 70%. Serotype distribution was estimated for IPD cases occurring 5 years or more after PCV10 or PCV13 introduction (ie, the mature period when the serotype distribution had stabilised) using multinomial Dirichlet regression, stratified by PCV product and age group (<5 years, 5-17 years, 18-49 years, and ≥50 years). FINDINGS: The analysis included cases occurring primarily between 2015 and 2018 from 42 PCV13 sites (63 362 cases) and 12 PCV10 sites (6806 cases) in 41 countries. Sites were mostly high income (36 [67%] of 54) and used three-dose or four-dose booster schedules (44 [81%]). At PCV10 sites, PCV10 serotypes caused 10·0% (95% CI 6·3-12·9) of IPD cases in children younger than 5 years and 15·5% (13·4-19·3) of cases in adults aged 50 years or older, while PCV13 serotypes caused 52·1% (49·2-65·4) and 45·6% (40·0-50·0), respectively. At PCV13 sites, PCV13 serotypes caused 26·4% (21·3-30·0) of IPD cases in children younger than 5 years and 29·5% (27·5-33·0) of cases in adults aged 50 years or older. The leading serotype at PCV10 sites was 19A in children younger than 5 years (30·6% [95% CI 18·2-43·1]) and adults aged 50 years or older (14·8% [11·9-17·8]). Serotype 3 was a top-ranked serotype, causing about 9% of cases in children younger than 5 years and 14% in adults aged 50 years or older at both PCV10 and PCV13 sites. Across all age and PCV10 or PCV13 strata, the proportion of IPD targeted by higher-valency PCVs beyond PCV13 was 4·1-9·7% for PCV15, 13·5-36·0% for PCV20, 29·9-53·8% for PCV21, 15·6-42·0% for PCV24, and 31·5-50·1% for PCV25. All top-ten ranked non-PCV13 serotypes are included in at least one higher-valency PCV. INTERPRETATION: The proportion of IPD due to serotypes included in PCVs in use was low in mature PCV10 and PCV13 settings. Serotype distribution differed between PCV10 and PCV13 sites and age groups. Higher-valency PCVs target most remaining IPD and are expected to extend impact. FUNDING: Bill & Melinda Gates Foundation as part of the WHO Pneumococcal Vaccines Technical Coordination Project.
Central Laboratory of Public Health Asunción Paraguay
Centre for Disease Control Department of Health and Community Services Darwin NT Australia
CIBER de Enfermedades Respiratorias Madrid Spain
CIBER Epidemiología y Salud Pública Madrid Spain
Communicable Diseases Centre National Institute of Public Health Ljubljana Slovenia
Costa Rican Institute for Research and Teaching in Nutrition and Health Tres Ríos Costa Rica
Department of Bacteria Parasites and Fungi Statens Serum Institut Copenhagen Denmark
Department of Clinical Microbiology Landspitali The National University Hospital Reykjavik Iceland
Department of Health Security Finnish Institute for Health and Welfare Helsinki Finland
Department of Infectious Diseases Italian National Institute of Health Rome Italy
Department of Microbiology Immunology and Transplantation KU Leuven Leuven Belgium
Department of Microbiology Public Health Agency of Sweden Solna Sweden
Department of Paediatrics University of Melbourne Parkville VIC Australia
Department of Pediatrics University of Calgary and Alberta Health Services Calgary AB Canada
Department of Pediatrics Yale New Haven Children's Hospital New Haven CT USA
Department of Public Health Ministry of Health and Care Services Oslo Norway
Department of Social and Preventive Medicine Laval University Québec QC Canada
Epidemiology Department Dirección General de Salud Pública Madrid Spain
Epidemiology Department Epiconcept Paris France
Epidemiology Team Institute of Environmental Science and Research Porirua New Zealand
European Centre for Disease Prevention and Control Solna Sweden
Faculty of Infectious and Tropical Diseases London School of Hygiene and Tropical Medicine London UK
Health Sciences Unit Faculty of Social Sciences Tampere University Tampere Finland
Immunisation and Countermeasures Division UK Health Security Agency London UK
Infectious Disease Epidemiology and Prevention Statens Serum Institut Copenhagen Denmark
Infectious Diseases Research Unit Mohammed 6 Center for Research and Innovation Rabat Morocco
Institute of Infection Veterinary and Ecological Sciences University of Liverpool Liverpool UK
Institute of Public Health Riga Stradiņš University Riga Latvia
Instituto de Salud Pública de Chile Santiago Chile
Johns Hopkins Bloomberg School of Public Health Baltimore MD USA
Malawi Liverpool Wellcome Programme Blantyre Malawi
Medicine Department International University of Catalunya Barcelona Spain
Molecular Microbiology Department Hospital Sant Joan de Déu Research Institute Barcelona Spain
Murdoch Children's Research Institute Parkville VIC Australia
National Institute of Public Health Prague Czech Republic
National Public Health Laboratory National Centre for Infectious Diseases Singapore
National Reference Centre for Streptococcus Pneumoniae University Hospitals Leuven Leuven Belgium
Navarre Institute for Health Research Pamplona Spain
New Vaccines Group Murdoch Children's Research Institute Parkville VIC Australia
Pan American Health Organization WHO Washington DC USA
Public Health Institute of Navarre Pamplona Spain
Royal College of Surgeons in Ireland Dublin Ireland
Toyama Institute of Health Toyama Japan
Vaccine Study Center Kaiser Permanente Oakland CA USA
WHO Regional Office for Africa Brazzaville Republic of the Congo
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009379
- 003
- CZ-PrNML
- 005
- 20250429134912.0
- 007
- ta
- 008
- 250415s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1473-3099(24)00588-7 $2 doi
- 035 __
- $a (PubMed)39706205
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Garcia Quesada, Maria $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: mgarci64@jhmi.edu
- 245 10
- $a Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis / $c M. Garcia Quesada, ME. Peterson, JC. Bennett, K. Hayford, SL. Zeger, Y. Yang, MK. Hetrich, DR. Feikin, AL. Cohen, A. von Gottberg, M. van der Linden, NM. van Sorge, LH. de Oliveira, S. de Miguel, I. Yildirim, DF. Vestrheim, JR. Verani, E. Varon, P. Valentiner-Branth, G. Tzanakaki, N. Sinkovec Zorko, LP. Setchanova, F. Serhan, KJ. Scott, JA. Scott, C. Savulescu, L. Savrasova, R. Reyburn, K. Oishi, JP. Nuorti, D. Napoli, JM. Mwenda, C. Muñoz-Almagro, E. Morfeldt, K. McMahon, A. McGeer, L. Mad'arová, GA. Mackenzie, M. Eugenia León, SN. Ladhani, KG. Kristinsson, J. Kozakova, J. Kleynhans, NP. Klein, JD. Kellner, S. Jayasinghe, PL. Ho, M. Hilty, MA. Harker-Jones, LL. Hammitt, M. Grgic-Vitek, C. Gilkison, R. Gierke, N. French, I. Diawara, S. Desmet, P. De Wals, T. Dalby, R. Dagan, M. Corcoran, E. Colzani, G. Chanto Chacón, J. Castilla, R. Camilli, M. Ang, K. Ampofo, SCG. Almeida, P. Alarcon, KL. O'Brien, M. Deloria Knoll, PSERENADE Team
- 520 9_
- $a BACKGROUND: Widespread use of pneumococcal conjugate vaccines (PCVs) has reduced vaccine-type invasive pneumococcal disease (IPD). We describe the serotype distribution of IPD after extensive use of ten-valent PCV (PCV10; Synflorix, GSK) and 13-valent PCV (PCV13; Prevenar 13, Pfizer) globally. METHODS: IPD data were obtained from surveillance sites participating in the WHO-commissioned Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project that exclusively used PCV10 or PCV13 (hereafter PCV10 and PCV13 sites, respectively) in their national immunisation programmes and had primary series uptake of at least 70%. Serotype distribution was estimated for IPD cases occurring 5 years or more after PCV10 or PCV13 introduction (ie, the mature period when the serotype distribution had stabilised) using multinomial Dirichlet regression, stratified by PCV product and age group (<5 years, 5-17 years, 18-49 years, and ≥50 years). FINDINGS: The analysis included cases occurring primarily between 2015 and 2018 from 42 PCV13 sites (63 362 cases) and 12 PCV10 sites (6806 cases) in 41 countries. Sites were mostly high income (36 [67%] of 54) and used three-dose or four-dose booster schedules (44 [81%]). At PCV10 sites, PCV10 serotypes caused 10·0% (95% CI 6·3-12·9) of IPD cases in children younger than 5 years and 15·5% (13·4-19·3) of cases in adults aged 50 years or older, while PCV13 serotypes caused 52·1% (49·2-65·4) and 45·6% (40·0-50·0), respectively. At PCV13 sites, PCV13 serotypes caused 26·4% (21·3-30·0) of IPD cases in children younger than 5 years and 29·5% (27·5-33·0) of cases in adults aged 50 years or older. The leading serotype at PCV10 sites was 19A in children younger than 5 years (30·6% [95% CI 18·2-43·1]) and adults aged 50 years or older (14·8% [11·9-17·8]). Serotype 3 was a top-ranked serotype, causing about 9% of cases in children younger than 5 years and 14% in adults aged 50 years or older at both PCV10 and PCV13 sites. Across all age and PCV10 or PCV13 strata, the proportion of IPD targeted by higher-valency PCVs beyond PCV13 was 4·1-9·7% for PCV15, 13·5-36·0% for PCV20, 29·9-53·8% for PCV21, 15·6-42·0% for PCV24, and 31·5-50·1% for PCV25. All top-ten ranked non-PCV13 serotypes are included in at least one higher-valency PCV. INTERPRETATION: The proportion of IPD due to serotypes included in PCVs in use was low in mature PCV10 and PCV13 settings. Serotype distribution differed between PCV10 and PCV13 sites and age groups. Higher-valency PCVs target most remaining IPD and are expected to extend impact. FUNDING: Bill & Melinda Gates Foundation as part of the WHO Pneumococcal Vaccines Technical Coordination Project.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a pneumokokové vakcíny $x aplikace a dávkování $7 D022242
- 650 12
- $a pneumokokové infekce $x prevence a kontrola $x epidemiologie $x mikrobiologie $7 D011008
- 650 _2
- $a mladiství $7 D000293
- 650 12
- $a séroskupina $7 D065288
- 650 12
- $a Streptococcus pneumoniae $x klasifikace $x imunologie $7 D013296
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a celosvětové zdraví $7 D014943
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a vakcíny konjugované $x aplikace a dávkování $7 D018074
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a očkovací programy $7 D017589
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Peterson, Meagan E $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 700 1_
- $a Bennett, Julia C $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 700 1_
- $a Hayford, Kyla $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 700 1_
- $a Zeger, Scott L $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 700 1_
- $a Yang, Yangyupei $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 700 1_
- $a Hetrich, Marissa K $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 700 1_
- $a Feikin, Daniel R $u WHO, Geneva, Switzerland
- 700 1_
- $a Cohen, Adam L $u WHO, Geneva, Switzerland
- 700 1_
- $a von Gottberg, Anne $u Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 700 1_
- $a van der Linden, Mark $u Reference Laboratory for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, Aachen, Germany
- 700 1_
- $a van Sorge, Nina M $u Medical Microbiology and Infection Prevention, Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
- 700 1_
- $a de Oliveira, Lucia H $u Pan American Health Organization, WHO, Washington, DC, USA
- 700 1_
- $a de Miguel, Sara $u CIBER de Enfermedades Respiratorias, Madrid, Spain; Epidemiology Department, Dirección General de Salud Pública, Madrid, Spain
- 700 1_
- $a Yildirim, Inci $u Department of Pediatrics, Yale New Haven Children's Hospital, New Haven, CT, USA
- 700 1_
- $a Vestrheim, Didrik F $u Department of Public Health, Ministry of Health and Care Services, Oslo, Norway
- 700 1_
- $a Verani, Jennifer R $u Division of Global Health Protection, Center for Global Health, Centers for Disease Control and Prevention, Nairobi, Kenya; Division of Bacterial Diseases, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA
- 700 1_
- $a Varon, Emmanuelle $u National Reference Centre for Pneumococci, Data Research Department, Intercommunal Hospital of Créteil, Créteil, France
- 700 1_
- $a Valentiner-Branth, Palle $u Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
- 700 1_
- $a Tzanakaki, Georgina $u National Meningitis Reference Laboratory, Department of Public Health Policy, School of Public Health, University of West Attica, Athens, Greece
- 700 1_
- $a Sinkovec Zorko, Nadja $u Communicable Diseases Centre, National Institute of Public Health, Ljubljana, Slovenia
- 700 1_
- $a Setchanova, Lena P $u University Multiprofile Hospital for Active Treatment Saint Ivan Rilski, Clinical Microbiology Laboratory, Sofia, Bulgaria
- 700 1_
- $a Serhan, Fatima $u WHO, Geneva, Switzerland
- 700 1_
- $a Scott, Kevin J $u Bacterial Respiratory Infection Service, Scottish Microbiology Reference Laboratory, NHS Greater Glasgow and Clyde, Glasgow, UK
- 700 1_
- $a Scott, J Anthony $u Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Coast, Kilifi, Kenya
- 700 1_
- $a Savulescu, Camelia $u Epidemiology Department, Epiconcept, Paris, France
- 700 1_
- $a Savrasova, Larisa $u Institute of Public Health, Riga Stradiņš University, Riga, Latvia
- 700 1_
- $a Reyburn, Rita $u Murdoch Children's Research Institute, Parkville, VIC, Australia
- 700 1_
- $a Oishi, Kazunori $u Toyama Institute of Health, Toyama, Japan
- 700 1_
- $a Nuorti, J Pekka $u Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland; Health Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland
- 700 1_
- $a Napoli, Daniela $u Clinical Bacteriology Service, Department of Bacteriology, National Institute for Infectious Diseases (INEI-ANLIS) "Dr Carlos G Malbrán", Buenos Aires, Argentina
- 700 1_
- $a Mwenda, Jason M $u WHO Regional Office for Africa, Brazzaville, Republic of the Congo
- 700 1_
- $a Muñoz-Almagro, Carmen $u CIBER Epidemiología y Salud Pública, Madrid, Spain; Medicine Department, International University of Catalunya, Barcelona, Spain; Molecular Microbiology Department, Hospital Sant Joan de Déu Research Institute, Barcelona, Spain
- 700 1_
- $a Morfeldt, Eva $u Department of Microbiology Public Health Agency of Sweden, Solna, Sweden
- 700 1_
- $a McMahon, Kimberley $u Centre for Disease Control, Department of Health and Community Services, Darwin, NT, Australia
- 700 1_
- $a McGeer, Allison $u Toronto Invasive Bacterial Diseases Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Mad'arová, Lucia $u National Reference Centre for Pneumococcal and Haemophilus Diseases, Regional Authority of Public Health, Banská Bystrica, Slovakia
- 700 1_
- $a Mackenzie, Grant A $u New Vaccines Group, Murdoch Children's Research Institute, Parkville, VIC, Australia; Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Banjul, The Gambia
- 700 1_
- $a Eugenia León, Maria $u Central Laboratory of Public Health, Asunción, Paraguay
- 700 1_
- $a Ladhani, Shamez N $u Immunisation and Countermeasures Division, UK Health Security Agency, London, UK
- 700 1_
- $a Kristinsson, Karl G $u Department of Clinical Microbiology, Landspitali-The National University Hospital, Reykjavik, Iceland
- 700 1_
- $a Kozakova, Jana $u National Institute of Public Health, Prague, Czech Republic
- 700 1_
- $a Kleynhans, Jackie $u Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 700 1_
- $a Klein, Nicola P $u Vaccine Study Center, Kaiser Permanente, Oakland, CA, USA
- 700 1_
- $a Kellner, James D $u Department of Pediatrics, University of Calgary and Alberta Health Services, Calgary, AB, Canada
- 700 1_
- $a Jayasinghe, Sanjay $u National Centre for Immunisation Research and Surveillance and Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW, Australia
- 700 1_
- $a Ho, Pak-Leung $u Department of Microbiology and Carol Yu Centre for Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China
- 700 1_
- $a Hilty, Markus $u Swiss National Reference Centre for Invasive Pneumococci, Institute for Infectious Diseases, University of Bern, Bern, Switzerland
- 700 1_
- $a Harker-Jones, Marcella A $u Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Anchorage, AK, USA
- 700 1_
- $a Hammitt, Laura L $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Coast, Kilifi, Kenya
- 700 1_
- $a Grgic-Vitek, Marta $u Communicable Diseases Centre, National Institute of Public Health, Ljubljana, Slovenia
- 700 1_
- $a Gilkison, Charlotte $u Epidemiology Team, Institute of Environmental Science and Research, Porirua, New Zealand
- 700 1_
- $a Gierke, Ryan $u Division of Bacterial Diseases, National Center for Immunizations and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA
- 700 1_
- $a French, Neil $u Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK; Malawi Liverpool Wellcome Programme, Blantyre, Malawi
- 700 1_
- $a Diawara, Idrissa $u Infectious Diseases Research Unit, Mohammed VI Center for Research & Innovation (CM6RI), Rabat, Morocco; Mohammed VI University of Sciences and Health, Mohammed VI Higher Institute of Biosciences and Biotechnologies (UM6SS), Casablanca, Morocco
- 700 1_
- $a Desmet, Stefanie $u Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium; National Reference Centre for Streptococcus Pneumoniae, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a De Wals, Philippe $u Department of Social and Preventive Medicine, Laval University, Québec, QC, Canada
- 700 1_
- $a Dalby, Tine $u Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark; Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark
- 700 1_
- $a Dagan, Ron $u The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
- 700 1_
- $a Corcoran, Mary $u Irish Meningitis and Sepsis Reference Laboratory, Children's Health Ireland at Temple Street, Dublin, Ireland; Royal College of Surgeons in Ireland, Dublin, Ireland
- 700 1_
- $a Colzani, Edoardo $u European Centre for Disease Prevention and Control, Solna, Sweden
- 700 1_
- $a Chanto Chacón, Grettel $u Costa Rican Institute for Research and Teaching in Nutrition and Health, Tres Ríos, Costa Rica
- 700 1_
- $a Castilla, Jesús $u CIBER Epidemiología y Salud Pública, Madrid, Spain; Public Health Institute of Navarre, Pamplona, Spain; Navarre Institute for Health Research, Pamplona, Spain
- 700 1_
- $a Camilli, Romina $u Department of Infectious Diseases, Italian National Institute of Health, Rome, Italy
- 700 1_
- $a Ang, Michelle $u National Public Health Laboratory, National Centre for Infectious Diseases, Singapore
- 700 1_
- $a Ampofo, Krow $u Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT, USA
- 700 1_
- $a Almeida, Samanta C G $u National Laboratory for Meningitis and Pneumococcal Infections, Center of Bacteriology, Institute Adolfo Lutz, São Paulo, Brazil
- 700 1_
- $a Alarcon, Pedro $u Instituto de Salud Pública de Chile, Santiago, Chile
- 700 1_
- $a O'Brien, Katherine L $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; WHO, Geneva, Switzerland
- 700 1_
- $a Deloria Knoll, Maria $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 710 2_
- $a PSERENADE Team
- 773 0_
- $w MED00006437 $t Lancet. Infectious diseases $x 1474-4457 $g Roč. 25, č. 4 (2025), s. 445-456
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39706205 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134907 $b ABA008
- 999 __
- $a ok $b bmc $g 2311014 $s 1246460
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 25 $c 4 $d 445-456 $e 20241217 $i 1474-4457 $m Lancet. Infectious diseases $n Lancet Infect Dis $x MED00006437
- GRA __
- $a 001 $p World Health Organization $2 International
- LZP __
- $a Pubmed-20250415
